Galmed Pharmaceuticals Ltd.
NASDAQTotal Valuation
Galmed Pharmaceuticals Ltd. carries a market capitalization of 4.01M, placing it among publicly traded companies globally. Its enterprise value stands at -10.54M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.01M |
| Enterprise Value | -10.54M |
Share Statistics
Galmed Pharmaceuticals Ltd. currently has 125,174.00 shares outstanding.
| Shares Outstanding | 125,174.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.04 |
| P/TBV Ratio | 0.09 |
| P/FCF Ratio | -0.43 |
| P/OCF Ratio | -0.43 |
Financial Position
Galmed Pharmaceuticals Ltd. maintains a current ratio of 4.16, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.16 |
| Quick Ratio | 4.11 |
| Debt / Equity | 1.01 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -68.21 |
| Return on Assets (ROA) | -55.03 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Galmed Pharmaceuticals Ltd.'s stock has declined approximately -64.59854% over the past 52 weeks. The 50-day moving average sits at 4.40, while the 200-day moving average is 5.36.
| Beta (5Y) | N/A |
| 52-Week Price Change | -64.59854% |
| 50-Day Moving Average | 4.40 |
| 200-Day Moving Average | 5.36 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -9.96M, while operating income came in at -9.96M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -9.96M |
| Pretax Income | -11.34M |
| Net Income | -11.34M |
| EBITDA | -9.96M |
| EBIT | -9.96M |
| Earnings Per Share (EPS) | -13.84 |
Balance Sheet
Galmed Pharmaceuticals Ltd. holds 11.23M in cash and equivalents against 129,000.00 in total debt, resulting in a net debt position of -2.88M. Total book value stands at 12.74M, with working capital of 8.90M providing operational flexibility.
| Cash & Cash Equivalents | 11.23M |
| Total Debt | 129,000.00 |
| Net Debt | -2.88M |
| Equity (Book Value) | 12.74M |
| Book Value Per Share | 101.76 |
| Working Capital | 8.90M |
Cash Flow
Galmed Pharmaceuticals Ltd. produced -8.54M in operating cash flow over the past twelve months.
| Operating Cash Flow | -8.54M |
| Capital Expenditures | N/A |
| Free Cash Flow | -8.54M |
| FCF Per Share | -10.42 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -481.13 |
| FCF Yield | -234.25 |
Stock Splits
Galmed Pharmaceuticals Ltd.'s most recent stock split took place on August 19, 2026 with a 8:1 split ratio.
| Last Split Date | 8/19/2026 |
| Split Ratio | 8:1 |
Scores
Galmed Pharmaceuticals Ltd. posts an Altman Z-Score of -27.20, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -27.20 |